Muxol (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Muxol, is a mucolytic presented as an oral dosage form for oral use. It helps to thin respiratory mucus and is used to relieve cough with thick sputum in conditions such as bronchitis and chronic obstructive pulmonary disease. GNH USA supplies Muxol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ambroxol Hydrochloride acts on the respiratory tract to reduce mucus viscosity and improve clearance, making it useful in several pulmonary conditions. - Cough with thick mucus: facilitates expectoration and eases breathing. - Bronchitis: reduces sputum thickness and supports recovery. - Chronic obstructive pulmonary disease (COPD): aids mucus clearance and helps manage chronic cough.

Ambroxol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Taste alteration: a transient bitter or metallic taste. - Nausea: mild stomach upset after oral administration. - Diarrhea: loose stools in some patients. - Headache: occasional mild headache. - Skin rash: mild erythema or itching. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: rash, swelling, or anaphylaxis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: abnormal liver function tests. - Eosinophilia: increased eosinophil count. - Hematologic abnormalities: rare blood dyscrasias.

Before using Ambroxol, consider the following safety measures. - Assess renal function: dose adjustment may be needed in severe impairment. - Use with caution in asthma: monitor for bronchospasm. - Avoid in known hypersensitivity: discontinue if allergic signs appear. - Monitor gastrointestinal irritation: advise patients to report persistent nausea or abdominal pain. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Ambroxol may interact with other medicines; awareness helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may increase ambroxol plasma levels. - Concurrent use with other mucolytics: risk of excessive airway irritation. - Antitussives containing codeine: may counteract expectorant effect.

Moderate Interactions (Monitor Closely): - Antihistamines: possible reduction in secretory response. - Bronchodilators (e.g., albuterol): monitor for additive respiratory effects. - Certain antibiotics (e.g., macrolides): may increase gastrointestinal side‑effects.